Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 10:13:1180888.
doi: 10.3389/fonc.2023.1180888. eCollection 2023.

Body composition as a predictor of oncological outcome in patients with non-muscle-invasive bladder cancer receiving intravesical instillation after transurethral resection of bladder tumor

Liang-Kang Huang  1 , Yu-Ching Lin  2 , Hai-Hua Chuang  3 , Cheng-Keng Chuang  1 , See-Tong Pang  1 , Chun-Te Wu  1 , Ying-Hsu Chang  4 , Kai-Jie Yu  1 , Po-Hung Lin  1 , Hung-Cheng Kan  1 , Yuan-Cheng Chu  1 , Wei-Kang Hung  5 , Ming-Li Hsieh  1 , I-Hung Shao  1
Affiliations

Body composition as a predictor of oncological outcome in patients with non-muscle-invasive bladder cancer receiving intravesical instillation after transurethral resection of bladder tumor

Liang-Kang Huang et al. Front Oncol. .

Abstract

Introduction: Body status, categorized as sarcopenia or obesity and assessed using body mass index and body composition, affects the outcome of bladder cancer patients. However, studies comparing disease progression, recurrence, or overall survival in patients with non-muscle-invasive bladder cancer (NMIBC) with different body compositions are lacking. Therefore, we conducted a retrospective study to identify the impact of body composition, sarcopenia, and obesity on the oncological prognosis of patients with NMIBC who underwent transurethral resection of bladder tumor (TURBT) with Bacillus Calmette-Guerin (BCG) intravesical instillation (IVI).

Methods: Patients with NMIBC who had undergone TURBT with adjuvant IVI with BCG from March 2005 to April 2021 were included. Body composition parameters were evaluated using computed tomography images of the third lumbar vertebrae and further categorized by sarcopenia and obesity. Oncological outcomes including recurrence-free survival (RFS), progression-free survival, and overall survival (OS) after treatment were analyzed.

Results: A total of 269 patients were enrolled. Subcutaneous adipose tissue (SAT) density was a significant predictor of RFS, whereas psoas muscle density was a significant predictor of OS in the multivariate analysis. Patients with sarcopenia but without obesity tolerated significantly fewer BCG IVIs than patients without sarcopenia or obesity. Patients with sarcopenia had poorer RFS and OS than those without sarcopenia. In contrast, patients with obesity had better OS than those without obesity.

Discussion: Body composition parameters, including SAT density and psoas muscle density, emerged as significant predictors of OS and RFS, respectively. Hence, our findings indicate that body composition is a helpful measurement to assess the oncological outcomes of patients with NMIBC.

Keywords: bladder cancer; body composition; intravesical instillation; non-muscle-invasive bladder cancer; obesity; sarcopenia; transurethral resection.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of patient selection. MIBC, muscle-invasive bladder cancer; NMIBC, non-muscle-invasive bladder cancer; Tis, carcinoma in situ; Ta, tumors confined to the mucosa; Tl, tumors invading the lamina propria; IVI, intravesical instillation; TURBT, transurethral resection of bladder tumor; CT, computed tomography.
Figure 2
Figure 2
Kaplan–Meier survival curves of recurrence-free, progression-free, and overall survival analyses for patients with obesity and sarcopenia.
See this image and copyright information in PMC

References

    1. Sanchez A, Kissel S, Coletta A, Scott J, Furberg H. Impact of body size and body composition on bladder cancer outcomes: risk stratification and opportunity for novel interventions. Urol Oncol (2020) 38:713–8. doi: 10.1016/j.urolonc.2020.03.017 - DOI - PMC - PubMed
    1. Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, et al. . EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance Bacillus Calmette-Guerin. Eur Urol (2016) 69:60–9. doi: 10.1016/j.eururo.2015.06.045 - DOI - PubMed
    1. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol (2006) 49:466–5; discussion 475. doi: 10.1016/j.eururo.2005.12.031 - DOI - PubMed
    1. Choi JB, Lee EJ, Han KD, Hong SH, Ha US. Estimating the impact of body mass index on bladder cancer risk: stratification by smoking status. Sci Rep (2018) 8:947. doi: 10.1038/s41598-018-19531-7 - DOI - PMC - PubMed
    1. Bandera EV, Qin B, Lin Y, Zeinomar N, Xu B, Chanumolu D, et al. . Association of body mass index, central obesity, and body composition with mortality among black breast cancer survivors. JAMA Oncol (2021) 7:1–10. doi: 10.1001/jamaoncol.2021.1499 - DOI - PMC - PubMed